NMS-P528

NMS-P528 (gradient concentrations; 72 h) potently inhibits the proliferation of a panel of 30 distinct tumor cell lines, with a mean IC₅₀ of 0.202 nM following 72-hour treatment^[1].
NMS-P528 (gradient concentrations; 72-144 h) circumvents multi-drug resistance in A2780/ADR ovarian cancer cells, and exhibits similar antiproliferative activity against parental A2780 cells, with resistance indices of 1.2 (72 h) and 1.8 (144 h)^[1].
NMS-P528 (30 μM; up to 24 h) has a short plasma half-life in mouse, rat, and cynomolgus monkey plasma, which are 0.46, 0.22, and 0.34 h respectively, due to rapid spirocyclization and subsequent inactivation^[1].
NMS-P528 (gradient concentrations; 144 h) potently inhibits the proliferation of the tumor cell lines HCC1569, HCC1954, NCI-N87, Hs-578-T and SW620, with a mean IC₅₀ value ranging from 0.010 to 0.025 nM after 144 h of treatment^[1].
NMS-P528 (1 nM; 24-72 h) induces DNA damage, cell cycle arrest and apoptosis in HCC1954 breast cancer cells, which is evidenced by increased positive rate of p-H2AX, decreased BrdUrd incorporation and expanded sub-G₁ cell population^[1].
NMS-P528 induces apoptosis in human neuroblastoma cell lines SK-N-AS, COG-N-453, NBL-S, Felix and NB-1 at its IC₅₀ concentration, which is confirmed by an increased annexin V-positive rate^[2].
NMS-P528, delivered via EV20/NMS-P945, exerts potent, target-dependent cytotoxic activity against a variety of tumor cell lines in vitro, with stronger activity in HER-3-highly expressing cells including MDA-MB-435, Sk-mel 24, DU145, Fadu, OVCAR-8, SNU638 and WM115^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.